PFE - Pfizer Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—General
New York,
United States
Type: Equity
PFE price evolution
PFE
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Jan 2024 | 2 Aug 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1052 | $719 | $2853 | $3148 |
| Short term investments | $6048 | $11209 | $9837 | $41033 |
| Net receivables | $15087 | $10989 | $11177 | $13425 |
| Inventory | $11447 | $10892 | $10189 | $10310 |
| Total current assets | $37825 | $42415 | $43333 | $73347 |
| Long term investments | $11148 | $11613 | $15368 | $14239 |
| Property, plant & equipment | $18957 | $18803 | $18940 | $17488 |
| Goodwill & intangible assets | $129685 | $132126 | $132683 | $91751 |
| Total noncurrent assets | $178368 | $178680 | $183168 | $141009 |
| Total investments | $17196 | $22822 | $25205 | $55272 |
| Total assets | $216193 | $221095 | $226501 | $220168 |
| Current liabilities | ||||
| Accounts payable | $5106 | $5591 | $6710 | $6081 |
| Deferred revenue | $2528 | $2502 | $2700 | $2204 |
| Short long term debt | $11944 | $8232 | $10350 | $2548 |
| Total current liabilities | $43819 | $40497 | $47794 | $34647 |
| Long term debt | $57506 | $61307 | $61538 | $61356 |
| Total noncurrent liabilities | $84399 | $88040 | $89419 | $86681 |
| Total debt | $69450 | $69539 | $71888 | $63596 |
| Total liabilities | $128493 | $128537 | $137213 | $121149 |
| Shareholders' equity | ||||
| Retained earnings | $116596 | $121318 | $118353 | $128796 |
| Other shareholder equity | -$7815 | -$7758 | -$7961 | -$7990 |
| Total shareholder equity | $87700 | $92282 | $89014 | $96934 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2853 | $416 | $1944 | $1784 |
| Short term investments | $9837 | $22316 | $29125 | $10437 |
| Net receivables | $11177 | $10952 | $11479 | $7930 |
| Inventory | $10189 | $8981 | $9059 | $8046 |
| Total current assets | $43333 | $51259 | $59693 | $35067 |
| Long term investments | $15368 | $15069 | $21526 | $20262 |
| Property, plant & equipment | $18940 | $19276 | $14882 | $13900 |
| Goodwill & intangible assets | $132683 | $94745 | $74354 | $78048 |
| Total noncurrent assets | $183168 | $145946 | $121783 | $119162 |
| Total investments | $25205 | $37385 | $50651 | $30699 |
| Total assets | $226501 | $197205 | $181476 | $154229 |
| Current liabilities | ||||
| Accounts payable | $6710 | $6809 | $5578 | $4309 |
| Deferred revenue | $2700 | $2520 | $3067 | |
| Short long term debt | $10350 | $2945 | $2241 | $2703 |
| Total current liabilities | $47794 | $42138 | $42671 | $25920 |
| Long term debt | $61538 | $32884 | $36195 | $37133 |
| Total noncurrent liabilities | $89419 | $59150 | $61342 | $64836 |
| Total debt | $71888 | $35829 | $38436 | $39836 |
| Total liabilities | $137213 | $101545 | $104013 | $90756 |
| Shareholders' equity | ||||
| Retained earnings | $118353 | $125656 | $103394 | $96770 |
| Other shareholder equity | -$7961 | -$8525 | -$5897 | -$11688 |
| Total shareholder equity | $89014 | $95661 | $77201 | $63238 |
| (in millions $) | 30 Jul 2024 | 31 Mar 2024 | 31 Jan 2024 | 2 Aug 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13283 | $14879 | $14249 | $12734 |
| Cost of revenue | $3379 | |||
| Gross Profit | $10515 | $11500 | $7584 | $9332 |
| Operating activities | ||||
| Research & development | $2493 | |||
| Selling, general & administrative | $3495 | |||
| Total operating expenses | $7475 | $8078 | $7709 | $7215 |
| Operating income | $3422 | |||
| Income from continuing operations | ||||
| EBIT | $3408 | |||
| Income tax expense | -$134 | $293 | -$795 | -$71 |
| Interest expense | -$876 | $2422 | $99 | |
| Net income | ||||
| Net income | $41 | $3115 | -$3369 | $2327 |
| Income (for common shares) | $3115 | |||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $58496 | $100330 | $81288 | $41908 |
| Cost of revenue | $34344 | $30821 | $8692 | |
| Gross Profit | $40707 | $65986 | $50467 | $33216 |
| Operating activities | ||||
| Research & development | $11428 | $13829 | $9405 | |
| Selling, general & administrative | $13677 | $12703 | $11615 | |
| Total operating expenses | $27899 | $31259 | $26156 | $25725 |
| Operating income | $34727 | $24311 | $7491 | |
| Income from continuing operations | ||||
| EBIT | $34700 | $23832 | $10093 | |
| Income tax expense | -$1115 | $3328 | $1852 | $477 |
| Interest expense | $1986 | |||
| Net income | ||||
| Net income | $2119 | $31372 | $21980 | $9616 |
| Income (for common shares) | $31372 | $21979 | $9616 | |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 2 Aug 2023 |
|---|---|---|---|---|
| Net income | $41 | $3115 | -$3369 | |
| Operating activities | ||||
| Depreciation | $1731 | $1736 | $1670 | |
| Business acquisitions & disposals | $3491 | -$43405 | ||
| Stock-based compensation | $206 | $220 | $121 | |
| Total cash flows from operations | -$1781 | $1090 | $5240 | |
| Investing activities | ||||
| Capital expenditures | -$637 | -$704 | -$1044 | |
| Investments | $5256 | -$1056 | $33438 | |
| Total cash flows from investing | $4600 | $1732 | -$10996 | -$22170 |
| Financing activities | ||||
| Dividends paid | -$2380 | -$2372 | -$2315 | -$4618 |
| Sale and purchase of stock | ||||
| Net borrowings | -$16 | -$2173 | $7775 | |
| Total cash flows from financing | -$2459 | -$4931 | $5442 | $24403 |
| Effect of exchange rate | -$18 | -$28 | -$1 | -$7 |
| Change in cash and equivalents | $343 | -$2137 | -$316 | $2230 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $2119 | $31372 | $21980 | $9616 |
| Operating activities | ||||
| Depreciation | $6290 | $5064 | $5191 | $4777 |
| Business acquisitions & disposals | -$43430 | -$19037 | ||
| Stock-based compensation | $525 | $872 | $1182 | $756 |
| Total cash flows from operations | $8700 | $29267 | $32580 | $14403 |
| Investing activities | ||||
| Capital expenditures | -$3907 | -$3236 | -$2711 | -$2791 |
| Investments | $15239 | $6682 | -$19517 | -$1672 |
| Total cash flows from investing | -$32278 | -$15783 | -$22546 | -$4271 |
| Financing activities | ||||
| Dividends paid | -$9247 | -$8983 | -$8729 | -$8440 |
| Sale and purchase of stock | -$2000 | $425 | ||
| Net borrowings | $35945 | -$3516 | -$1103 | -$12755 |
| Total cash flows from financing | $26066 | -$14834 | -$9816 | -$9649 |
| Effect of exchange rate | -$40 | -$165 | -$59 | -$8 |
| Change in cash and equivalents | $2448 | -$1515 | $159 | $475 |
News
Fundamentals
| Market cap | $165.87B |
|---|---|
| Enterprise value | $234.27B |
| Shares outstanding | 5.67B |
| Revenue | $55.15B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $2.11B |
| Revenue Q/Q | -27.34% |
| Revenue Y/Y | N/A |
| P/E ratio | 78.46 |
|---|---|
| EV/Sales | 4.25 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 3.01 |
| P/B ratio | 1.74 |
| Book/Share | 16.85 |
| Cash/Share | 0.19 |
| EPS | $0.37 |
|---|---|
| ROA | 0.96% |
| ROE | 2.31% |
| Debt/Equity | 1.54 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.86 |
| Quick ratio | 0.60 |